Kymera Therapeutics price target raised to $52 from $48 at Stifel

Stifel raised the firm’s price target on Kymera Therapeutics to $52 from $48 and keeps a Buy rating on the shares. The firm’s recent research has built confidence that robust anti-tumor activity for KT-333 in PTCL will be demonstrated at its year-end phase 1 clinical update, the analyst tells investors. Further, regulatory paths suggest a single-arm ORR of more than 25% is approvable.